Advanced

Treatment of HIV infection: Swedish recommendations 2009

Josephson, Filip; Albert, Jan; Flamholc, Leo LU ; Gisslen, Magnus; Karlstrom, Olof; Moberg, Lars; Naver, Lars; Svedhem, Veronica; Svennerholm, Bo and Sonnerborg, Anders (2009) In Scandinavian Journal of Infectious Diseases 41(11-12). p.788-807
Abstract
On 4 previous occasions, in 2002, 2003, 2005 and 2007, the Swedish Medical Products Agency (Lakemedelsverket) and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection. In November 2008, an expert group under the guidance of RAV once more revised the guidelines, of which this is a translation into English. The most important updates in the present guidelines include the following: (a) treatment initiation is now recommended at a CD4 cell count of approximately 350/mu l; (b) new recommendations for first-line therapy: abacavir/lamivudine or tenofovir/emtricitabine in combination with efavirenz or a boosted protease inhibitor (PI/r); (c) an increased focus on... (More)
On 4 previous occasions, in 2002, 2003, 2005 and 2007, the Swedish Medical Products Agency (Lakemedelsverket) and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection. In November 2008, an expert group under the guidance of RAV once more revised the guidelines, of which this is a translation into English. The most important updates in the present guidelines include the following: (a) treatment initiation is now recommended at a CD4 cell count of approximately 350/mu l; (b) new recommendations for first-line therapy: abacavir/lamivudine or tenofovir/emtricitabine in combination with efavirenz or a boosted protease inhibitor (PI/r); (c) an increased focus on reducing the use of antiretroviral drugs that may cause lipoatrophy; (d) an emphasis on quality assurance of HIV care through the use of InfCare HIV; (e) considerably altered recommendations for the initiation of antiretroviral therapy in children. All infants (<1 y) should start antiretroviral therapy, regardless of immune status. Also, absolute CD4+ cell counts, rather than percentage, may be used to guide treatment initiation in children above the age of 5 y. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Infectious Diseases
volume
41
issue
11-12
pages
788 - 807
publisher
Informa Healthcare
external identifiers
  • wos:000272974600001
  • scopus:70450233644
ISSN
1651-1980
DOI
10.3109/00365540903214322
language
English
LU publication?
yes
id
e78a9a4a-def4-4fbd-9f04-741bcc9ea8c5 (old id 1531863)
date added to LUP
2010-01-28 17:14:18
date last changed
2017-08-27 04:56:19
@article{e78a9a4a-def4-4fbd-9f04-741bcc9ea8c5,
  abstract     = {On 4 previous occasions, in 2002, 2003, 2005 and 2007, the Swedish Medical Products Agency (Lakemedelsverket) and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection. In November 2008, an expert group under the guidance of RAV once more revised the guidelines, of which this is a translation into English. The most important updates in the present guidelines include the following: (a) treatment initiation is now recommended at a CD4 cell count of approximately 350/mu l; (b) new recommendations for first-line therapy: abacavir/lamivudine or tenofovir/emtricitabine in combination with efavirenz or a boosted protease inhibitor (PI/r); (c) an increased focus on reducing the use of antiretroviral drugs that may cause lipoatrophy; (d) an emphasis on quality assurance of HIV care through the use of InfCare HIV; (e) considerably altered recommendations for the initiation of antiretroviral therapy in children. All infants (&lt;1 y) should start antiretroviral therapy, regardless of immune status. Also, absolute CD4+ cell counts, rather than percentage, may be used to guide treatment initiation in children above the age of 5 y.},
  author       = {Josephson, Filip and Albert, Jan and Flamholc, Leo and Gisslen, Magnus and Karlstrom, Olof and Moberg, Lars and Naver, Lars and Svedhem, Veronica and Svennerholm, Bo and Sonnerborg, Anders},
  issn         = {1651-1980},
  language     = {eng},
  number       = {11-12},
  pages        = {788--807},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Infectious Diseases},
  title        = {Treatment of HIV infection: Swedish recommendations 2009},
  url          = {http://dx.doi.org/10.3109/00365540903214322},
  volume       = {41},
  year         = {2009},
}